{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:13:30Z","timestamp":1785816810910,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-024-00602-y","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T16:01:39Z","timestamp":1735920099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-456X","authenticated-orcid":false,"given":"Luigi","family":"Barrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gangitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"1","key":"602_CR1","doi-asserted-by":"publisher","first-page":"e3748","DOI":"10.1002\/dmrr.3748","volume":"40","author":"L Verde","year":"2024","unstructured":"Verde L, et al. Obesogenic environments as major determinants of a disease: it is time to re-shape our cities. Diabetes Metab Res Rev. 2024;40(1):e3748.","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"602_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/obr.12551","volume":"18","author":"GA Bray","year":"2017","unstructured":"Bray GA, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715\u201323. This position statement of the World Obesity Federation frames obesity not just as a condition, but as a chronic, relapsing disease driven by environmental factors and genetic susceptibility, highlighting the need for comprehensive approaches to its prevention and treatment.","journal-title":"Obes Rev"},{"key":"602_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2023.03.008","volume":"92","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Excess body weight: novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023;92:16\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"602_CR4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/ijo.2015.59","volume":"39","author":"FL Greenway","year":"2015","unstructured":"Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188\u201396.","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"602_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13679-022-00481-1","volume":"11","author":"G Muscogiuri","year":"2022","unstructured":"Muscogiuri G, et al. Mediterranean Diet and obesity-related disorders: what is the evidence? Curr Obes Rep. 2022;11(4):287\u2013304.","journal-title":"Curr Obes Rep"},{"issue":"3","key":"602_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40618-023-02258-2","volume":"47","author":"L Barrea","year":"2024","unstructured":"Barrea L, et al. Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism. J Endocrinol Invest. 2024;47(3):487\u2013500.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"602_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s13668-024-00560-w","volume":"13","author":"L Barrea","year":"2024","unstructured":"Barrea L, et al. A New nomenclature for the very low-calorie ketogenic Diet (VLCKD): very low-energy ketogenic therapy (VLEKT). Ketodiets and Nutraceuticals Expert panels: KetoNut, Italian Society of Nutraceuticals (SINut) and the Italian Association of Dietetics and Clinical Nutrition (ADI). Curr Nutr Rep. 2024;13(3):552\u20136.","journal-title":"Curr Nutr Rep"},{"issue":"2","key":"602_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000515381","volume":"14","author":"G Muscogiuri","year":"2021","unstructured":"Muscogiuri G, et al. European Guidelines for Obesity Management in adults with a very low-calorie ketogenic Diet: a systematic review and Meta-analysis. Obes Facts. 2021;14(2):222\u201345.","journal-title":"Obes Facts"},{"issue":"2","key":"602_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s13679-023-00502-7","volume":"12","author":"V Guglielmi","year":"2023","unstructured":"Guglielmi V, et al. Beyond Weight loss: added benefits could Guide the choice of Anti-obesity medications. Curr Obes Rep. 2023;12(2):127\u201346.","journal-title":"Curr Obes Rep"},{"issue":"3","key":"602_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.numecd.2014.12.001","volume":"25","author":"A Menotti","year":"2015","unstructured":"Menotti A, Puddu PE. How the Seven Countries Study contributed to the definition and development of the Mediterranean diet concept: a 50-year journey. Nutr Metab Cardiovasc Dis. 2015;25(3):245\u201352.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"602_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.numecd.2012.02.005","volume":"23","author":"E Kesse-Guyot","year":"2013","unstructured":"Kesse-Guyot E, et al. Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a 6-year prospective study. Nutr Metab Cardiovasc Dis. 2013;23(7):677\u201383.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"g6674","DOI":"10.1136\/bmj.g6674","volume":"349","author":"M Crous-Bou","year":"2014","unstructured":"Crous-Bou M, et al. Mediterranean diet and telomere length in nurses\u2019 Health Study: population based cohort study. BMJ. 2014;349:g6674.","journal-title":"BMJ"},{"issue":"6","key":"602_CR13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1017\/S0007114515000318","volume":"113","author":"F Prinelli","year":"2015","unstructured":"Prinelli F, et al. Mediterranean diet and other lifestyle factors in relation to 20-year all-cause mortality: a cohort study in an Italian population. Br J Nutr. 2015;113(6):1003\u201311.","journal-title":"Br J Nutr"},{"key":"602_CR14","doi-asserted-by":"crossref","unstructured":"Mancini JG et al. Systematic Review of the Mediterranean Diet for Long-Term Weight Loss. Am J Med, 2016. 129(4): pp. 407\u2013415 e4. **This systematic review indicates that the Mediterranean diet is superior to low-fat diets for long-term weight loss but leads to comparable weight loss and reductions in cardiovascular risk factors when compared to other diets in individuals with obesity and seeking to lose weight.","DOI":"10.1016\/j.amjmed.2015.11.028"},{"issue":"11","key":"602_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40618-019-01061-2","volume":"42","author":"M Caprio","year":"2019","unstructured":"Caprio M, et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 2019;42(11):1365\u201386.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"602_CR16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12020-014-0192-3","volume":"47","author":"B Moreno","year":"2014","unstructured":"Moreno B, et al. Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine. 2014;47(3):793\u2013805.","journal-title":"Endocrine"},{"issue":"3","key":"602_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12020-016-1050-2","volume":"54","author":"B Moreno","year":"2016","unstructured":"Moreno B, et al. Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease. Endocrine. 2016;54(3):681\u201390.","journal-title":"Endocrine"},{"key":"602_CR18","doi-asserted-by":"crossref","unstructured":"Cicero AF, et al. Middle and Long-Term Impact of a very low-carbohydrate ketogenic Diet on Cardiometabolic factors: a Multi-Center, cross-sectional, clinical study. Volume 22. High Blood Press Cardiovasc Prev; 2015. pp. 389\u201394. 4.","DOI":"10.1007\/s40292-015-0096-1"},{"key":"602_CR19","doi-asserted-by":"crossref","unstructured":"Moriconi E et al. Very-Low-Calorie Ketogenic Diet as a safe and Valuable Tool for Long-Term Glycemic Management in patients with obesity and type 2 diabetes. Nutrients, 2021. 13(3).","DOI":"10.3390\/nu13030758"},{"key":"602_CR20","doi-asserted-by":"crossref","unstructured":"Correa LL et al. Severe type 2 diabetes (T2D) remission using a very low-calorie ketogenic diet (VLCKD). Endocrinol Diabetes Metab Case Rep, 2022. 2022.","DOI":"10.1530\/EDM-22-0295"},{"key":"602_CR21","doi-asserted-by":"crossref","unstructured":"Perticone M et al. Ketogenic Diet-Induced weight loss is Associated with an increase in vitamin D levels in obese adults. Molecules, 2019. 24(13).","DOI":"10.3390\/molecules24132499"},{"issue":"2","key":"602_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"602_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2174\/1389450118666170227153940","volume":"18","author":"SP Bhat","year":"2017","unstructured":"Bhat SP, Sharma A. Current drug targets in obesity pharmacotherapy - A review. Curr Drug Targets. 2017;18(8):983\u201393.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"602_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/nyas.13542","volume":"1411","author":"A Velazquez","year":"2018","unstructured":"Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018;1411(1):106\u201319.","journal-title":"Ann N Y Acad Sci"},{"issue":"9741","key":"602_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595\u2013605.","journal-title":"Lancet"},{"issue":"16","key":"602_CR26","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1080\/14656566.2016.1244527","volume":"17","author":"KH Saunders","year":"2016","unstructured":"Saunders KH, Igel LI, Aronne LJ. An update on naltrexone\/bupropion extended-release in the treatment of obesity. Expert Opin Pharmacother. 2016;17(16):2235\u201342.","journal-title":"Expert Opin Pharmacother"},{"key":"602_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","volume":"92","author":"E Pilitsi","year":"2019","unstructured":"Pilitsi E, et al. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism. 2019;92:170\u201392.","journal-title":"Metabolism"},{"issue":"1","key":"602_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obes (Silver Spring). 2011;19(1):110\u201320.","journal-title":"Obes (Silver Spring)"},{"issue":"12","key":"602_CR29","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022\u20139.","journal-title":"Diabetes Care"},{"issue":"5","key":"602_CR30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obes (Silver Spring). 2013;21(5):935\u201343.","journal-title":"Obes (Silver Spring)"},{"key":"602_CR31","unstructured":"Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep, 2021. 10(1): pp. 14\u201330. * In this review, the authors demonstrated that the weight-loss efficacy of new anti-obesity drugs shows a placebo-subtracted weight reduction (%) over at least 12 months, ranging from 2.9\u20136.8% for the following drugs: phentermine\/topiramate (6.8%), liraglutide (5.4%), naltrexone\/bupropion (4.0%), orlistat (2.9%), and lorcaserin (3.1%)."},{"issue":"4","key":"602_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3803\/EnM.2014.29.4.410","volume":"29","author":"WS Jeon","year":"2014","unstructured":"Jeon WS, Park CY. Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Endocrinol Metab (Seoul). 2014;29(4):410\u20137.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"602_CR33","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41366-021-00831-4","volume":"45","author":"S Wharton","year":"2021","unstructured":"Wharton S, et al. Extended-release naltrexone\/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. Int J Obes (Lond). 2021;45(8):1687\u201395.","journal-title":"Int J Obes (Lond)"},{"key":"602_CR34","doi-asserted-by":"publisher","first-page":"101436","DOI":"10.1016\/j.eclinm.2022.101436","volume":"49","author":"CW le Roux","year":"2022","unstructured":"le Roux CW, et al. The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. EClinicalMedicine. 2022;49:101436.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"602_CR35","first-page":"CD007654","volume":"1","author":"A Siebenhofer","year":"2021","unstructured":"Siebenhofer A, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2021;1(1):CD007654.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"602_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/oby.21726","volume":"25","author":"A Halseth","year":"2017","unstructured":"Halseth A, et al. Method-of-use study of naltrexone sustained release (SR)\/bupropion SR on body weight in individuals with obesity. Obes (Silver Spring). 2017;25(2):338\u201345.","journal-title":"Obes (Silver Spring)"},{"key":"602_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jad.2021.04.017","volume":"289","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, et al. Psychiatric Safety and Weight loss efficacy of Naltrexone\/bupropion as add-on to antidepressant therapy in patients with obesity or overweight. J Affect Disord. 2021;289:167\u201376.","journal-title":"J Affect Disord"},{"issue":"2","key":"602_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7570\/jomes20010","volume":"29","author":"BY Kim","year":"2020","unstructured":"Kim BY, et al. Current long-term pharmacotherapies for the management of obesity. J Obes Metab Syndr. 2020;29(2):99\u2013109.","journal-title":"J Obes Metab Syndr"},{"issue":"10","key":"602_CR39","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, et al. Effect of naltrexone-bupropion on major adverse Cardiovascular events in overweight and obese patients with Cardiovascular Risk factors: a Randomized Clinical Trial. JAMA. 2016;315(10):990\u20131004.","journal-title":"JAMA"},{"issue":"9","key":"602_CR40","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen LB, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664\u20139.","journal-title":"J Med Chem"},{"issue":"4","key":"602_CR41","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409\u201339.","journal-title":"Physiol Rev"},{"issue":"1","key":"602_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/en.2014-1675","volume":"156","author":"KM Heppner","year":"2015","unstructured":"Heppner KM, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology. 2015;156(1):255\u201367.","journal-title":"Endocrinology"},{"issue":"6","key":"602_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843\u201354.","journal-title":"Int J Obes (Lond)"},{"issue":"12","key":"602_CR44","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4140\/TCP.n.2016.685","volume":"31","author":"KR Manigault","year":"2016","unstructured":"Manigault KR, Thurston MM. Liraglutide: A Glucagon-Like Peptide-1 agonist for Chronic Weight Management. Consult Pharm. 2016;31(12):685\u201397.","journal-title":"Consult Pharm"},{"issue":"1","key":"602_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0\u00a0mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"10077","key":"602_CR46","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"issue":"4","key":"602_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"602_CR48","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/dom.13160","volume":"20","author":"A McGovern","year":"2018","unstructured":"McGovern A, et al. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(4):1040\u20133.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"602_CR49","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1185\/03007995.2013.821056","volume":"29","author":"SM Curkendall","year":"2013","unstructured":"Curkendall SM, et al. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2013;29(10):1275\u201386.","journal-title":"Curr Med Res Opin"},{"key":"602_CR50","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/PPA.S106821","volume":"10","author":"WH Polonsky","year":"2016","unstructured":"Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299\u2013307.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"602_CR51","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.clinthera.2016.05.009","volume":"38","author":"CV Spain","year":"2016","unstructured":"Spain CV, et al. Self-reported barriers to adherence and persistence to treatment with Injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653\u2013e16641.","journal-title":"Clin Ther"},{"issue":"11\u201312","key":"602_CR52","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s13300-022-01322-z","volume":"13","author":"C Uzoigwe","year":"2022","unstructured":"Uzoigwe C, et al. Increased Healthcare Resource use and costs after discontinuation of Liraglutide in patients with type 2 diabetes from a commercial- and Medicaid-Insured Claims Database. Diabetes Ther. 2022;13(11\u201312):1861\u201374.","journal-title":"Diabetes Ther"},{"issue":"11","key":"602_CR53","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443\u201351.","journal-title":"Int J Obes (Lond)"},{"issue":"6","key":"602_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/dom.13985","volume":"22","author":"T Papathanasiou","year":"2020","unstructured":"Papathanasiou T, et al. Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0\u00a0mg: a model-based approach. Diabetes Obes Metab. 2020;22(6):969\u201377.","journal-title":"Diabetes Obes Metab"},{"key":"602_CR55","unstructured":"Bartelt K, Deckert J, Joyce B. Mast C, Deckert J, Gracianette M, Joyce B. Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide. Epic Research.https:\/\/epicresearch.org\/articles\/many-patients-maintain-weight-loss-a-year-after-stopping-semaglutide-and-liraglutide.Accessed on April 8, 2024."},{"key":"602_CR56","doi-asserted-by":"publisher","unstructured":"El Karkafi R, Gebara T, Salem M, Kamel J, El Khoury G, Zalal M, Fakhoury M. Ketogenic diet and inflammation: implications for mood and anxiety disorders. Adv Exp Med Biol. 2023;1411:537\u2013554. https:\/\/doi.org\/10.1007\/978-981-19-7376-5_23","DOI":"10.1007\/978-981-19-7376-5_23"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-024-00602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-024-00602-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-024-00602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T17:14:54Z","timestamp":1735924494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-024-00602-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s13679-024-00602-y","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"13 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1"}}